Innovative vaccines for a healthier world
Interview with CEO Bent Frandsen
Next Event
-
Mon01Apr2024Thu04Apr2024Washington D.C.
World Vaccine Congress Washington 2024
Early April, we look forward to sending a team of ExpreS2ion executives to the World Vaccine Congress in Washington D.C. The company's CSO Farshad Guirakhoo will be formally representing ExpreS2ion with a speech on Preclinical proof of concept for a novel VLP-based vaccine candidate for treatment of HER2+ breast cancers on April 3 at 12:25pm in the session on Cancer Immunotherapy.
Learn more on World Vaccine Congress Washington 2024
Latest News
ExpreS2ion to present in investor and R&D events in March
Hørsholm, Denmark, 29 February 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.
Read moreExpreS2ion’s Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic’s Clinical Phase III Study for the COVID-19 Vaccine
Hørsholm, Denmark, 21 February 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today announces that AdaptVac ApS (“AdaptVac”) has received 10 million EUR as a result of Bavarian Nordic having completed the clinical Phase III study of the COVID-19 vaccine ABNCoV2. The board of AdaptVac, in line with authority granted through AdaptVac’s…
Read moreExpreS2ion announces financial results for the fourth quarter and full-year 2023
Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.
Read more